Paclitaxel and Mitoxantrone in Metastatic Breast Cancer: A Phase II Trial of the Italian Oncology Group for Cancer Research

References

• Fossati R., Confalonieri C., Torri V., Ghislandi E., Penna A., Pistotti V., Tinazzi A., Liberati A. Cytotoxic and hormonal treatment for metastatic breast cancer: a systemic review of publisher randomized trials involving 31,510 women. J. Clin. Cancer 1998; 16: 3439–3460
   Google Scholar
• Harris J. R., Lippman M. E., Veronesi U., Willett W. Medical progress: breast cancer. N. Engl. J. Med. 1992; 327(7)473–480, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Rowinsky E. K., Cazenave L. A., Donehower R. C. Taxol a novel investigational antimicrotubule agent. J. Natl. Cancer Inst. 1990; 82: 1247–1259, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Rowinsky E. K., Donehower R. C. The clinical pharmacology of Paclitaxel (Taxol). Semin. Oncol. 1993; 20: 16–25, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Holmes F. A., Walters R. S., Theriault R. L. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst. 1991; 83: 1797–1805, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Gianni L., Capri G., Munzone E., Straneo M. Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines. Semin. Oncol. 1994; 21(suppl 8)29–33, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Abrams J. S., Vena D. A., Baltz J., Adams J., Montello M., Christian M., Onetto N., Desmond-Hellmann S., Canetta R., Friedman M. A., Arbuk S. G. Paclitaxel activity in heavily pre-treated breast cancer: A national cancer institute treatment referral center trial. J. Clin. Oncol. 1995; 13: 2056–2065, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Wilson W. H., Berg S. L., Bryant G., Wittes R. E., Bates S., Fojo A., Steinberg S. M., Goldspiel B. R., Herdt J., O'Shaughnessy J., Balis F. M., Chabner B. A. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J. Clin. Oncol. 1994; 12: 1621–1629, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Eisenhauer E. A., Bokkel Huinink W. W., Swenerton K. D., Gianni L., Myles J., Van de Burg M. E.L., Kerr I., Vermoken J. B., Buser K., Colombo N., Bacon M., Santabàrbara P., Onetto B., Winograd B., Canetta R. European–Canadian randomized trial of Paclitaxel in relapsed ovarian cancer: high dose versus low dose and long versus short infusion. J. Clin. Oncol. 1994; 12: 2654–2666, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Nabholtz J. M., Gelmon K., Bontenbal M., Spielmann M., Catimel G., Conte P., Klaasen U., Namer M., Bonneterre J., Fumoleau P., Winograd B. Multicenter, randomized comparative study of two doses of Paclitaxel in patients with metastatic breast cancer. J. Clin. Oncol. 1996; 14: 1858–1867, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Clemons M., Leahy M., Valle J., Jayson G., Ranson M., Howell A. Review of recent trials of chemotherapy for advanced breast cancer: the taxanes. Eur. J. Cancer 1997; 33: 2183–2193, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gianni L., Munzone E., Capri G., Fulfaro F., Tarenzi E., Villani F., Spreafico C., Laffranchi A., Caraceni A., Martini C., Stefanelli M., Valagussa P., Bonadonna G. Paclitaxel by 3 hour Infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose finding and sequence-finding study. J. Clin. Oncol. 1995; 13: 2688–2699, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Frassineti G. L., Zoli W., Silvestro L., Serra P., Milandri C., Tienghi A., Gianni L., Gentile A., Salzano E., Amadori D. Paclitaxel plus Doxorubicin in breast cancer: an Italian experience. Semin. Oncol. 1997; 24(suppl 17)19–25
   Google Scholar
• Dombernowsky P., Boesgaard M., Andersen E., Jensen B. V. Doxorubicin plus Paclitaxel in advanced breast cancer. Semin. Oncol. 1997; 24(Suppl 17)15–18
   Google Scholar
• Hainsworth J. D. The use of Mitoxantrone in the treatment of breast cancer. Semin. Oncol. 1995; 22(suppl 1)17–20, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Pavesi L., Preti P., Da Prada G., Pedrazoli P., Poggi G., Robustelli della Cuna G. Epirubicin versus Mitoxantrone in combination chemotherapy for metastatic breast cancer. Anticancer Res. 1995; 15: 495–502, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Alonso M. C., Tabernero J. M., Ojeda B., Llanos M., Solà C., Climent M. A., Seguì M. A., Lopez J. J. A phase III randomized trial of cyclophosphamide, Mitoxantrone, and 5-Fluorouracil (CNF) versus Cyclophosphamide, Adriamycin, and 5-Fluorouracil (CAF) in patients with metastatic breast cancer. Breast Cancer Res. Treat. 1995; 34: 15–24, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Green J. A., Slater A. J., Campbell I. R., Kelly V. Advanced breast cancer: a randomized study of doxorubicin or mitoxantrone in combination with Cyclophosphamide and Vincristine. Breast Cancer Res. Treat. 1996; 39: 155–163, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Henderson I. C., Allegra J. C., Woodcock T., Wolff S., Bryan S., Catwright K., Dukart G., Henry D. Randomized clinical trial comparing Mitoxantrone with Doxorubicin in previously treated patients with metastatic breast cancer. J. Clin. Oncol. 1989; 7: 560–571, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Shenkenberg T. D., Von Hoff D. D. Mitoxantrone: a new anticancer drug with significant clinical activity. Ann. Intern. Med. 1986; 105: 67–81, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Di Costanzo F., Sdrobolini A., Manzione L., Bilancia D., Acito L., Gasperoni S., Valenti L., Fioriti L., Angiona S., Giustini L. Dose intensification of mitoxantrone in combination with paclitaxel in advanced breast cancer: a phase II study. Breast Cancer Res. Treat. 1999; 54: 165–171, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication 48, World Health Organization, GenevaSwitzerland 1979
   Google Scholar
• Hryniuk W. M., Figuredo A., Goodyear M. Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin. Oncol. 1987; 14(suppl 4)3–11, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Luck H. J., Thomssen C., DuBois A. Interim analysis of a phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer. Semin. Oncol. 1996; 23(suppl 1)33–36, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Paridaens R. Efficacy of paclitaxel or doxorubicin used as single agents in advanced breast cancer: a literature survey. Semin. Oncol. 1998; 25(suppl 12)3–6, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Pagani O. Taxoids in combination with epirubicin: the search for improved outcomes in breast cancer. Semin. Oncol. 1998; 25(suppl 12)23–26, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Fleming F., Janisch L., Vogelzang N. J., Vokes E. E., Ratain M. J. Phase I study of escalating doses of Mitoxantrone and Paclitaxel with granulocyte-macrophage colony stimulating factor support. Cancer 1996; 77: 2308–2312, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Panagos G. E. Treatment of advanced and relapsing breast cancer with combination of Paclitaxel and Mitoxantrone. Semin. Oncol. 1997; 24(suppl 3)17–21
   PubMedGoogle Scholar
• Alexopoulos A., Kouroussis C., Malamos N. Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as first-line chemotherapy in metastatic breast cancer: a multicenter phase II study. Ann. Oncol. 2001; 12(6)793–798, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Harvey J., Cantrell J. J., Campbell M., Cartmell A., Urba W. Mitoxantrone and paclitaxel combination chemotherapy in metastatic breast cancer. Cancer Investig. 2001; 19(3)225–233, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Greco F. A., Hainsworth J. D. Paclitaxel with Mitoxantrone with or without 5-Fluorouracil, and high dose Leucovorin in the treatment of metastatic breast cancer. Semin. Oncol. 1997; 24(suppl 17)61–64
   Google Scholar